US M&A and equity raisings
3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
Deals dated after 30 September 2026 are still being collected.
7 deals · US$7.6bndisclosed · Ophthalmology · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Aug 2026 | TYRVAYA (varenicline solution) nasal spray 0.03 mg | Viatris | Harrow | Asset sale | Announced | 30.0 | Pharma+1 | Cravath, Swaine & Moore (sell-side) |
| Aug 2026 | Alkeus Pharmaceuticals | – | Tarsus Pharmaceuticals | Acquisition | Announced | 450.0 | Biotech+2 | Jefferies (sell-side)Latham & Watkins (sell-side)Barclays (buy-side)Gunderson Dettmer (buy-side) |
| Jul 2026 | iRenix Medical | – | Tarsus Pharmaceuticals | Acquisition | Announced | 75.0 | Ophthalmology+2 | Piper Sandler (sell-side)DLA Piper (sell-side)Gunderson Dettmer (buy-side) |
| May 2026 | Perfuse Therapeutics | – | Bayer | Acquisition | Announced | 300.0 | Biotech+2 | Goodwin (sell-side) |
| Mar 2026 | Apellis Pharmaceuticals | – | Biogen | Acquisition | Announced | 5,600.0 | Biotech+2 | Lazard (buy-side)Evercore (sell-side)Wachtell, Lipton, Rosen & Katz (sell-side)WilmerHale (sell-side)Cravath, Swaine & Moore (buy-side) |
| Mar 2026 | EyeSouth Partners’ retina business | EyeSouth Partners | Cencora | Asset sale | Announced | 1,100.0 | Healthcare Services+1 | Jefferies (sell-side)Kirkland & Ellis (sell-side)BofA Securities (buy-side)Citi (buy-side)Sidley Austin (buy-side) |
| Feb 2026 | LKC Technologies | DW Healthcare Partners | AMETEK | Acquisition | Announced | – | Medtech+2 | William Blair (sell-side) |
Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built